KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Non-Current Debt (2016 - 2025)

Idexx Laboratories (IDXX) has 17 years of Non-Current Debt data on record, last reported at $374.8 million in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 16.66% year-over-year to $374.8 million; the TTM value through Dec 2025 reached $374.8 million, down 16.66%, while the annual FY2025 figure was $374.8 million, 16.66% down from the prior year.
  • Non-Current Debt reached $374.8 million in Q4 2025 per IDXX's latest filing, roughly flat from $374.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $780.1 million in Q2 2021 and bottomed at $374.8 million in Q3 2025.
  • Average Non-Current Debt over 5 years is $625.6 million, with a median of $658.6 million recorded in 2022.
  • Peak YoY movement for Non-Current Debt: grew 11.67% in 2021, then fell 28.57% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $775.2 million in 2021, then fell by 10.43% to $694.4 million in 2022, then decreased by 10.3% to $622.9 million in 2023, then fell by 27.79% to $449.8 million in 2024, then dropped by 16.66% to $374.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $374.8 million in Q4 2025, $374.8 million in Q3 2025, and $449.8 million in Q2 2025.